In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors have been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.
Zappone, E., Defina, M., Aprile, L., Gozzetti, A., Bartalucci, G., Bocchia, M. (2016). FLT3 inhibitors in the management of acute myeloid leukemia. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, [Epub ahead of print].
FLT3 inhibitors in the management of acute myeloid leukemia
APRILE, LARA;GOZZETTI, ALESSANDRO;BOCCHIA, MONICA
2016-01-01
Abstract
In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors have been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1006961
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo